Related Experiment Videos
Subantimicrobial dose doxycycline for acne and rosacea
1The Department of Dermatology, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA. drb@bikowskimd.com
Skinmed
|December 16, 2003
Summary
Subantimicrobial dose doxycycline shows promise for treating acne and rosacea by reducing inflammation. Further research is recommended for these challenging skin conditions.
Area of Science:
- Dermatology
- Pharmacology
Background:
- Acne vulgaris and rosacea are chronic inflammatory skin conditions with significant psychosocial impact.
- Current treatments often involve prolonged antimicrobial use, leading to resistance and adverse events.
- Tetracyclines possess anti-inflammatory properties beyond their antimicrobial effects.
Purpose of the Study:
- To investigate the efficacy of subantimicrobial dose doxycycline in treating acne and rosacea.
- To explore novel therapeutic strategies for inflammatory dermatoses.
Main Methods:
- A double-blind, placebo-controlled trial for moderate facial acne.
- An open-label study for rosacea treatment.
- Evaluation of subantimicrobial dose doxycycline's anti-inflammatory mechanisms (anticollagenolytic, anti-metalloproteinase, cytokine down-regulation).
Main Results:
- Early trials suggest clinical utility of subantimicrobial dose doxycycline.
- Demonstrated anti-inflammatory properties of tetracyclines at subantimicrobial doses.
Conclusions:
- Subantimicrobial dose doxycycline presents a potential new treatment avenue for acne and rosacea.
- Further clinical investigation is warranted to confirm its benefits in these conditions.